| Year |
Citation |
Score |
| 2014 |
Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer. 110: 1977-84. PMID 24556618 DOI: 10.1038/Bjc.2014.91 |
0.328 |
|
| 2014 |
Young MPD, Sherk C, Bleam M, Barnette M, Ganji G, Hoang B, Tunstead J, Bellovin D, Los G, Minthorn E, Kumar R. Abstract LB-236: Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230 Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-236 |
0.423 |
|
| 2014 |
Bellovin DI, Palencia S, Hestir K, Lee E, DeYoung MP, Brennan T, Los G, Baker K. Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC Cancer Research. 74: 5449-5449. DOI: 10.1158/1538-7445.Am2014-5449 |
0.379 |
|
| 2014 |
Gemo AT, Deshpande AM, Palencia S, Bellovin DI, Brennan TJ, Patil NS, Huang C, Los G, Pierce KL. Abstract 5446: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification Cancer Research. 74: 5446-5446. DOI: 10.1158/1538-7445.Am2014-5446 |
0.403 |
|
| 2014 |
Deshpande AM, Palencia S, Bellovin DI, Gemo AT, Giese T, Stohr B, Pierce KL, Los G. Abstract 2845: Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody Cancer Research. 74: 2845-2845. DOI: 10.1158/1538-7445.Am2014-2845 |
0.362 |
|
| 2013 |
Fang DD, Cao J, Jani JP, Tsaparikos K, Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, Zhu Z, Gu Y, Los G, Hostomsky Z, Vanarsdale T. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line. Frontiers of Medicine. 7: 462-76. PMID 23820871 DOI: 10.1007/S11684-013-0270-6 |
0.461 |
|
| 2013 |
Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, ... ... Los G, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Molecular Cancer Therapeutics. 12: 1002-15. PMID 23729402 DOI: 10.1158/1535-7163.Mct-12-0813 |
0.449 |
|
| 2013 |
Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Molecular Cancer Therapeutics. 12: 567-76. PMID 23493310 DOI: 10.1158/1535-7163.Mct-12-0798 |
0.404 |
|
| 2012 |
Michaud NR, Jani JP, Hillerman S, Tsaparikos KE, Barbacci-Tobin EG, Knauth E, Putz H, Campbell M, Karam GA, Chrunyk B, Gebhard DF, Green LL, Xu JJ, Dunn MC, Coskran TM, ... ... Los G, et al. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. Mabs. 4: 710-23. PMID 23007574 DOI: 10.4161/Mabs.22160 |
0.365 |
|
| 2012 |
Zhu Z, Shi M, Hu W, Estrella H, Engebretsen J, Nichols T, Briere D, Hosea N, Los G, Rejto PA, Fanjul A. Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. Bmc Genomics. 13: 355. PMID 22849360 DOI: 10.1186/1471-2164-13-355 |
0.352 |
|
| 2012 |
Zou HY, Li Q, Lee JH, Arango ME, Burgess K, Qiu M, Engstrom LD, Yamazaki S, Parker M, Timofeevski S, Cui JJ, McTigue M, Los G, Bender SL, Smeal T, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Molecular Cancer Therapeutics. 11: 1036-47. PMID 22389468 DOI: 10.1158/1535-7163.Mct-11-0839 |
0.422 |
|
| 2012 |
Wei P, Qiu M, Jiang I, Carroll C, Han G, Rymer I, Kraynov E, Wu A, Thibault S, Stone D, Gao Y, Sofia S, Gallo J, White J, Li G, ... ... Los G, et al. Abstract 3485: Inhibition of Notch signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells Cancer Research. 72: 3485-3485. DOI: 10.1158/1538-7445.Am2012-3485 |
0.43 |
|
| 2012 |
Kuruma H, Matsumoto H, Shiota M, Fanjul A, Briere D, Los G, Lamoureux F, Thomas C, Gleave M, Zoubeidi A. 972 A NOVEL ANTIANDROGEN PF-05234848 SUPPRESSES CASTRATION-RESISTANT AND MDV-3100-RESISTANT PROSTATE CANCER GROWTH
IN VITRO
AND
IN VIVO Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1071 |
0.332 |
|
| 2011 |
Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M, Hosea N, Kang P, Hu W, Engebretsen J, Briere D, ... ... Los G, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. Journal of Medicinal Chemistry. 54: 7693-704. PMID 21936524 DOI: 10.1021/Jm201059S |
0.347 |
|
| 2011 |
Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. Journal of the National Cancer Institute. 103: 334-46. PMID 21183737 DOI: 10.1093/Jnci/Djq509 |
0.378 |
|
| 2011 |
Mehta PP, Kung PP, Yamazaki S, Walls M, Shen A, Nguyen L, Gehring MR, Los G, Smeal T, Yin MJ. A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells. Cancer Letters. 300: 30-9. PMID 20926183 DOI: 10.1016/J.Canlet.2010.09.002 |
0.407 |
|
| 2011 |
Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 64-81. PMID 20852590 DOI: 10.1038/Modpathol.2010.189 |
0.329 |
|
| 2011 |
Shojaei F, Simmons BH, Lee JH, Wong A, Los G, Kan J, Christensen JG. Abstract 4480: Combination of a PI3K/mTOR inhibitor and a MEK inhibitor at suboptimal dose significantly inhibits growth of lung adenocarcinoma tumors in KrasG12D-LSL mice Cancer Research. 71: 4480-4480. DOI: 10.1158/1538-7445.Am2011-4480 |
0.381 |
|
| 2011 |
Tan W, Yang S, Looper D, Nowlin D, Huang Z, Los G, Jani JP. Abstract 305: EphB4 and EphrinB2 regulates ovarian cancer progression Cancer Research. 71: 305-305. DOI: 10.1158/1538-7445.Am2011-305 |
0.426 |
|
| 2011 |
Blasina A, Hallin JF, Tan W, Los G, Jani JP. Abstract 2549: Efficacy of the Chk1 inhibitor PF-00477736 and pemetrexed in human mesothelioma Cancer Research. 71: 2549-2549. DOI: 10.1158/1538-7445.Am2011-2549 |
0.433 |
|
| 2011 |
Wei P, Qiu M, Peng Q, Lippincott J, Zachwieja J, Kraynov E, Wu A, Han B, Stone D, Zhai W, Rymer I, Yang J, Gajiwala K, Yu X, Gao Y, ... ... Los G, et al. Abstract 1765: Inhibition of Notch signaling by a Notch1 monoclonal antibody induces robust anti-tumor efficacy in T-cell acute lymphoblastic leukemia and breast cancer Cancer Research. 71: 1765-1765. DOI: 10.1158/1538-7445.Am2011-1765 |
0.436 |
|
| 2010 |
Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, et al. PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5177-88. PMID 20829331 DOI: 10.1158/1078-0432.Ccr-10-1343 |
0.391 |
|
| 2010 |
Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2344-51. PMID 20371688 DOI: 10.1158/1078-0432.Ccr-09-2758 |
0.372 |
|
| 2010 |
Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Molecular Cancer Therapeutics. 9: 883-94. PMID 20354118 DOI: 10.1158/1535-7163.Mct-09-0915 |
0.441 |
|
| 2008 |
Zhang C, Lundgren K, Yan Z, Arango ME, Price S, Huber A, Higgins J, Troche G, Skaptason J, Koudriakova T, Nonomiya J, Yang M, O'Connor P, Bender S, Los G, et al. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Molecular Cancer Therapeutics. 7: 818-28. PMID 18413795 DOI: 10.1158/1535-7163.Mct-07-0440 |
0.372 |
|
| 2007 |
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics. 6: 3314-22. PMID 18089725 DOI: 10.1158/1535-7163.Mct-07-0365 |
0.396 |
|
| 2007 |
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Research. 67: 4408-17. PMID 17483355 DOI: 10.1158/0008-5472.Can-06-4443 |
0.401 |
|
| 2005 |
Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR, Carey TE. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Molecular Cancer Therapeutics. 4: 1096-104. PMID 16020667 DOI: 10.1158/1535-7163.Mct-05-0081 |
0.392 |
|
| 2002 |
de las Alas MM, Los G, Lin X, Kurdi-Haidar B, Manorek G, Howell SB. Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine. Molecular Pharmacology. 62: 1198-206. PMID 12391284 DOI: 10.1124/Mol.62.5.1198 |
0.311 |
|
| 2002 |
Los G, Yang F, Samimi G, Manorek G, Guerorguieva IM, Howell S, van Erp N, Breaux JK. Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry. 47: 66-71. PMID 11774355 DOI: 10.1002/Cyto.10037 |
0.376 |
|
| 2001 |
Onoda N, Nehmi A, Weiner D, Mujumdar S, Christen R, Los G. Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. Head & Neck. 23: 860-70. PMID 11592233 DOI: 10.1002/Hed.1125 |
0.364 |
|
| 2001 |
Lin X, Gately DP, Hom D, Mishima M, Los G, Howell SB. Quantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter. International Journal of Cancer. 91: 555-62. PMID 11251981 DOI: 10.1002/1097-0215(200002)9999:9999<::Aid-Ijc1083>3.0.Co;2-Q |
0.381 |
|
| 2001 |
Samimi G, Breaux J, Mishima M, Berry C, Howell S, Los G. Gene expression profiling of oxaliplatin-resistant cell lines Nature Genetics. 27: 84-84. DOI: 10.1038/87280 |
0.364 |
|
| 2001 |
Yang F, Manorek G, Los G. Unique expression patterns for paclitaxel, doxorubicin and cisplatin in breast carcinoma cells Nature Genetics. 27: 70-70. DOI: 10.1038/87188 |
0.318 |
|
| 2000 |
Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, Los G. Identification of genes differentially expressed in association with acquired cisplatin resistance. British Journal of Cancer. 83: 1047-54. PMID 10993653 DOI: 10.1054/Bjoc.2000.1420 |
0.357 |
|
| 2000 |
De Las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, D'Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G. Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel Cancer Chemotherapy and Pharmacology. 45: 381-388. PMID 10803921 DOI: 10.1007/S002800051006 |
0.324 |
|
| 1999 |
Johnsson A, Strand C, Los G. Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts. Cancer Chemotherapy and Pharmacology. 43: 348-352. PMID 10071988 DOI: 10.1007/S002800050906 |
0.406 |
|
| 1999 |
Los G, Johnson A, Yang F, Berry C, Howell S. Identification of genes differentially expressed in cisplatin-sensitive versus resistant tumour cells Nature Genetics. 23: 60-60. DOI: 10.1038/14357 |
0.369 |
|
| 1997 |
de las Alas MM, Aebi S, Fink D, Howell SB, Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. Journal of the National Cancer Institute. 89: 1537-41. PMID 9337351 DOI: 10.1093/Jnci/89.20.1537 |
0.393 |
|
| 1997 |
Trask DK, Zhu S, Carey TE, Wicha M, Bradford CR, Los G. Regulation of resistance to cisplatin in human squamous cell carcinoma cell lines Otolaryngology-Head and Neck Surgery. 117. DOI: 10.1016/S0194-5998(97)80091-5 |
0.367 |
|
| 1996 |
Hettinga JVE, Lemstra W, Meijer C, Los G, Vries EGEd, Konings AWT, Kampinga HH. Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. International Journal of Cancer. 67: 800-807. PMID 8824551 DOI: 10.1002/(Sici)1097-0215(19960917)67:6<800::Aid-Ijc8>3.0.Co;2-V |
0.397 |
|
| 1996 |
Los G, Blommaert fA, Barton R, Heath DD, den Engelse L, Hanchett C, Vicario D, Weisman R, Robbins KT, Howell SB. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemotherapy and Pharmacology. 37: 150-4. PMID 7497585 DOI: 10.1007/Bf00685642 |
0.364 |
|
| 1995 |
Gately DP, Jones JA, Christen R, Barton RM, Los G, Howell SB. Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. British Journal of Cancer. 70: 1102-6. PMID 7981060 DOI: 10.1038/Bjc.1994.455 |
0.373 |
|
| 1995 |
Nakata B, Albright KD, Barton RM, Howell SB, Los G. Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines Cancer Chemotherapy and Pharmacology. 35: 511-518. PMID 7882460 DOI: 10.1007/Bf00686837 |
0.394 |
|
| 1995 |
Kröning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB, Christen RD. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. British Journal of Cancer. 72: 615-9. PMID 7669570 DOI: 10.1038/Bjc.1995.382 |
0.419 |
|
| 1994 |
Christen RD, Isonishi S, Jones JA, Jekunen AP, Hom DK, Kröning R, Gately DP, Thiebaut FB, Los G, Howell SB. Signaling and drug sensitivity. Cancer Metastasis Reviews. 13: 175-89. PMID 7923549 DOI: 10.1007/Bf00689635 |
0.38 |
|
| 1994 |
Los G, Muggia FM. Platinum resistance. Experimental and clinical status. Hematology-Oncology Clinics of North America. 8: 411-429. DOI: 10.1016/S0889-8588(18)30179-5 |
0.316 |
|
| 1993 |
Muggia FM, Los G. Platinum resistance: Laboratory findings and clinical implications Stem Cells. 11: 182-193. PMID 8318904 DOI: 10.1002/Stem.5530110304 |
0.401 |
|
| Show low-probability matches. |